In This Article:
Insiders who bought US$216.4k worth of Indaptus Therapeutics, Inc.'s (NASDAQ:INDP) stock at an average buy price of US$2.09 over the last year may be disappointed by the recent 10% decrease in the stock. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$175.7k, which is not great.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for Indaptus Therapeutics
The Last 12 Months Of Insider Transactions At Indaptus Therapeutics
Over the last year, we can see that the biggest insider purchase was by insider Glen Anderson for US$216k worth of shares, at about US$2.34 per share. That means that an insider was happy to buy shares at above the current price of US$1.70. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Glen Anderson.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Indaptus Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Indaptus Therapeutics insiders own about US$4.5m worth of shares. That equates to 26% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Indaptus Therapeutics Tell Us?
It doesn't really mean much that no insider has traded Indaptus Therapeutics shares in the last quarter. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Indaptus Therapeutics and their transactions don't cause us concern. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 5 warning signs for Indaptus Therapeutics (1 can't be ignored) you should be aware of.